Company intelligence / Profile preview

Amira Advisors

San Diego, California, United Statesamiraadvisors.com ↗

Ownership: Private
Development stage: Other

Overview

At the time of its acquisition by Bristol Myers Squibb, Amira Pharmaceuticals had advanced its lead compound AM152, an LPA1 antagonist, through Phase I clinical trials with plans for Phase IIa studies targeting idiopathic pulmonary fibrosis and systemic sclerosis. The company also had preclinical programs targeting autotaxin and FLAP inhibitors for inflammatory and fibrotic diseases. No commercialized products were reported prior to acquisition.

Therapeutic areas: PulmonologyCardiovascularRheumatologyImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

GlaxoSmithKline (for development of FLAP inhibitors)Roche Holding AG (research alliance/licensing option)

Beyond the preview

Go deeper on Amira Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amira Advisors.

Explore the full profile